Testing two immunotherapy drugs for cancer that has spread to the brain

This trial is testing whether two medications—niraparib and dostarlimab—work better together to treat cancer that has spread to the brain. Niraparib works by blocking a protein that helps cancer cells repair themselves, while dostarlimab helps your immune system recognize and fight cancer cells. Researchers want to see if combining these two approaches can shrink brain tumors and improve outcomes for people with advanced cancer.

Cancer that spreads to the brain is very difficult to treat, and current options are limited. This medication combination may offer a new way to attack these tumors by targeting them from multiple angles at once—both by blocking cancer cell repair and by boosting the immune system.